SCHEMBL3277915

SCHEMBL3277915

COCCCOc1cccc(Oc2ccc(C3C(O)CNCC3OCc3ccc4c(c3)N(CCCOC)CCO4)cc2)c1

nearest known ligand 0.47

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
REN P00797 19/20 0.47
AXL P30530 1/20 0.33
MERTK Q12866 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13161131 1.00 REN (0.47) RENAXLMERTK
SCHEMBL8434744 1.00 REN (0.47) RENAXLMERTK
SCHEMBL8430145 0.98 REN (0.44) RENAXLMERTK
SCHEMBL3464666 0.98 REN (0.44) RENAXLMERTK
SCHEMBL13161138 0.98 REN (0.44) RENAXLMERTK
SCHEMBL4668025 0.97 REN (0.43) RENAXLMERTK
SCHEMBL13161120 0.97 REN (0.43) RENAXLMERTK
SCHEMBL13161112 0.96 REN (0.42) RENAXLMERTK
SCHEMBL3274355 0.96 REN (0.42) RENAXLMERTK
SCHEMBL8428845 0.96 REN (0.42) RENAXLMERTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7799779-B2 Substituted piperidines as renin inhibitors NOVARTIS AG (CH) 2010-09-21 US disclosed
EP-1863802-B1 SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS NOVARTIS AG (CH) 2010-06-16 EP disclosed
US-20090306064-A1 Substituted Piperidines as Renin Inhibitors NOVARTIS AG (CH) 2009-12-10 US disclosed
EP-1987834-A2 Substituted piperidines as therapeutic compounds Speedel Experimenta AG (CH) 2008-11-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306064-A1 Substituted Piperidines as Renin Inhibitors REN, AGTR1, ACE REN 1/4885AXL 3794/4885MERTK 4087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.